New paraoxonase 1 polymorphism I102V and the risk of prostate cancer in Finnish men

Journal of the National Cancer Institute

Volumn 95, Issue 11, 2003, Pages 812-818

  Marchesani, Marja ^a   Hakkarainen, Anna ^b   Tuomainen, Tomi Pekka ^b   Kaikkonen, Jari ^a   Pukkala, Eero ^c   Uimari, Pekka ^a   Seppälä, Eija ^d   Matikainen, Mika ^d   Kallioniemi, Olli P ^e   Schleutker, Johanna ^d   Lehtimäki, Terho ^d   Salonen, Jukka T ^a,f  

^a Oy Jurilab Ltd   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c FINNISH CANCER REGISTRY   (Finland)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

^e UNIVERSITY OF TURKU   (Finland)

^f Inner Savo Health Centre   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; CARCINOGEN; DNA; ISOLEUCINE; RADICAL; UNCLASSIFIED DRUG; VALINE; ESTERASE; PON1 PROTEIN, HUMAN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER RISK; CODON; COHORT ANALYSIS; CONTROLLED STUDY; DNA SEQUENCE; DRUG USE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; EXON; FAMILIAL CANCER; FINLAND; FOLLOW UP; GENE EXPRESSION; GENETIC POLYMORPHISM; HETEROZYGOSITY; HUMAN; LIPID SOLUBILITY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MUTATIONAL ANALYSIS; PHENOTYPE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RANDOMIZATION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; ALLELE; CASE CONTROL STUDY; ENZYMOLOGY; EPIDEMIOLOGY; GENE EXPRESSION REGULATION; GENETICS; GENOTYPE; HETEROZYGOTE; INCIDENCE; MIDDLE AGED; MUTATION; PROSTATE TUMOR; RISK; RISK FACTOR;

AGED; ALLELES; ARYLDIALKYLPHOSPHATASE; CASE-CONTROL STUDIES; ESTERASES; FINLAND; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HETEROZYGOTE; HUMANS; INCIDENCE; ISOLEUCINE; MALE; MIDDLE AGED; MUTATION; ODDS RATIO; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; SAMPLING STUDIES; VALINE;

EID: 0038380332     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/95.11.812     Document Type: Article

References (44)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000;50:7-33.
2. Finnish Cancer Registry. Cancer incidence in Finland 1998. Cancer statistics of The National Research and Development Centre for Welfare and Health. Cancer Society of Finland publication available at www.cancerregistry.fi/v2000/v2000002oi.html (year 2000).
3. Woolf CM. An investigation of the familial aspects of carcinoma of the prostate. Cancer 1960;13:739-44.
4. Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of prostate cancer. Prostate 1990;17:337-47.
5. Matikainen MP, Sankila R, Schleutker J, Kallioniemi OP, Pukkala EA. Nationwide cancer family ascertainment using Finnish Cancer Registry data on family names and places of birth for 35,761 prostate cancer patients. Int J Cancer 2000;88:307-12.
6. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer: analyses of cohorts of twins from Sweden, Denmark and Finland. N Engl J Med 2000;343:78-85.
7. Ames BN. Dietary carcinogens and anticarcinogens. Oxygen radicals and degenerative diseases. Science 1983;221:1256-64.
8. Goldstein BD, Witz G. Free radicals and carcinogenesis. Free Radic Res Commun 1990;11:3-10.
9. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993;3:73-6.
10. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 1996;14:334-6.
11. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998;394:284-7.
12. Weber WW. Influence of heredity on human sensitivity to environmental chemicals. Environ Mol Mutagen 1995;25 Suppl 26:102-14.
13. Kondo I, Yamamoto M. Genetic polymorphism of paraoxonase 1 (PON1) and susceptibility to Parkinson's disease. Brain Res 1998;806:271-3.
14. Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase. Gen Pharmacol 1998;31:329-36.
15. Leviev I, James RW. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 2000;20:516-21.
16. Sanghera DK, Aston CE, Saha N, Kamboh MI. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet 1998;62:36-44.
17. Hengle RA, Connelly PW, Scherer SW, Hanley AJ, Harris SB, Tsui LC, et al. Paraoxonase-2 gene (PON2) G148 variant associated with elevated fasting plasma glucose in noninsulin-dependent diabetes mellitus. J Clin Endocr Metab 1997;82:3373-7.
18. Salonen JT. Is there a continuing need for longitudinal epidemiologic research? The Kuopio Ischaemic Heart Disease Risk Factor Study. Ann Clin Res 1988;20:46-50.
19. Schleutker J, Matikainen M, Smith J, Koivisto P, Baffoe-Bonnie A, Kainu T, et al. A genetic epidemiological study of hereditary prostate cancer (HPC) in Finland: frequent HPCX linkage in families with late-onset disease. Clin Cancer Res 2000;6:4810-5.
20. Teppo L, Pukkala E, Lehtonen M. Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol 1994; 33:365-9.
21. Salonen JT, Malin R, Tuomainen TP, Nyyssonen K, Lakka TA, Lehtimaki T. Polymorphism in high density lipoprotein paraoxonase gene and risk of acute myocardial infarction in men: prospective nested case-control study. BMJ 1999;319:487-8.
22. Ihanainen M, Salonen R, Seppänen R, Salonen JT. Nutrition data collection in the Kuopio Ischaemic Heart Disease Risk Factor Study: nutrient intake of middle-aged Eastern Finnish men. Nutr Res 1989;9:597-604.
23. Lakka TA, Venäläinen JM, Rauramaa R, Salonen R, Tuomilehto J, Salonen JT. Relation of leisure-time physical activity and cardiorespiratory fitness to the risk of acute myocardial infarction in men. N Engl J Med 1994;330: 1549-54.
24. Salonen JT, Kaplan GA. Socioeconomic conditions and ischaemic heart disease. BMJ 1991;302:113-4.
25. Carter BS, Beauty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci U S A 1992; 89:3367-71.
26. Grönberg H, Damber L, Damber JE, Iselius L. Segregation analysis of prostate cancer in Sweden: support for dominant inheritance. Am J Epidemiol 1997;146:552-7.
27. Schaid DJ, McDonnell SK, Blute ML, Thibodeau SN. Evidence for autosomal dominant inheritance of prostate cancer. Am J Hum Genet 1998;62: 1425-38.
28. Smith JR, Freije D, Carpten JD, Gronberg H, Xu J, Isaacs SD, et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996;274:1371-4.
29. Carpten J, Nupponen N, Isaacs S, Sood R, Robbins C, Xu J, et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 2002;30:181-4.
30. Tavtigian SV, Simard J, Teng DH, Abtin V, Baumgard M, Beck A, et al. A candidate prostate cancer susceptibility gone at chromosome 17p. Nat Genet 2001;27:172-80.
31. Rebbeck TR, Walker AH, Zeigler-Johnson C, Weisburg S, Martin AM, Nathanson KL, et al. Association of HPC2/ELAC2 genotypes and prostate cancer. Am J Hum Genet 2000;67:1014-9.
32. Rökman A, Ikonen T, Mononen N, Autio V, Matikainen MP, Koivisto PA, et al. ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer. Cancer Res 2001;61:6038-41.
33. Wu YQ, Chen H, Rubin MA, Wojno KJ, Cooney KA. Loss of heterozygosity of the putative prostate cancer susceptibility gene HPC2/ELAC2 is uncommon in sporadic and familial prostate cancer. Cancer Res 2001;61: 8651-3.
34. Berthon P, Valeri A, Cohen-Akenine A, Drelon E, Paiss T, Wohr G, et al. Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet 1998;62:1416-24.
35. Xu J, Meyers D, Freije D, Isaacs S, Wiley K, Nusskern D, et al. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet 1998;20:175-9.
36. Gibbs M, Stanford JL, McIndoe RA, Jarvik GP, Kolb S, Goode EL, et al. Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet 1999;64:776-87.
37. Berry R, Schroeder JJ, French AJ, McDonnell SK, Peterson BJ, Cunningham JM, et al. Evidence for a prostate cancer-susceptibility locus on chromosome 20. Am J Hum Genet 2000;67:82-91.
38. Ostrander EA, Stanford JL. Genetics of prostate cancer: too many loci, too few genes. Am J Hum Genet 2000;67:1367-75.
39. Peters MA, Ostrander EA. Prostate cancer: simplicity to complexity. Nat Genet 2001;27:134-5.
40. Bock CH, Cunningham JM, McDonnell SK, Schaid DJ, Peterson BJ, Pavlic RJ, et al. Analysis of the prostate cancer susceptibility locus HPC20 in 172 families affected by prostate cancer. Am J Hum Genet 2001;68:795-801.
41. Markidakis NM, Ross RK, Pike MC, Crocitto LE, Kolonel LN, Pearce CL, et al. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 1999;354:975-8.
42. Stanford JL, Just JJ, Gibbs M, Wicklund KG, Neal CL, Blumenstein BA, et al. Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res 1997;57:1194-8.
43. Nwosu V, Carpten J, Trent JM, Sheridan R. Heterogeneity of genetic alterations in prostate cancer: evidence of the complex nature of the disease. Hum Mol Genet 2001;10:2313-8.
44. Fleshner NE, Klotz LH. Diet, androgens, oxidative stress and prostate cancer susceptibility. Cancer Metastasis Rev 1998-99;17:325-30.